Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

//Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ) said Friday they eradicated nearly all traces of hepatitis B virus in a Phase 2 study — sending Arrowhead stock careening toward a record high. On the stock market today, Arrowhead stock jumped 6.3% to 42.10. On Monday, shares hit a record high in intraday action of 42.29. Arrowhead stock broke out on Oct. 17, topping a buy point at 36.90 out of a cup base. Now, the stock is roughly 14% extended. CAN SLIM rules for investing suggest taking some profits when a stock rises 20%-25% above its buy point.

By | 2019-11-18T11:11:31-04:00 November 8th, 2019|News|Comments Off on Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

About the Author: